Search - tctmd.com

Displaying 401 - 420 of 841

Sort: Relevancy | Date

News Daily News

Long-term MI Risk Among Stable CAD Patients: Some Clues From CORONOR

Shelley Wood

April 24, 2017

News Daily News

Absorb Comparable to Xience in Economic Analysis, but BVS Safety Concerns Could Alter Balance

Michael O'Riordan

April 18, 2017

News Daily News

Treating In-Stent CTOs May Be Riskier Than De Novo CTOs Despite Similar Procedural Success

Yael L. Maxwell

April 17, 2017

News Opinion Fellow Talk

The Left Main Debate: What Does it Mean for the Future of Intervention?

Tiffany Patterson, MBBS

April 12, 2017

Presentation Fellows 2017

Stent Thrombosis and Restenosis

Presenter: Emmanouil S. Brilakis, Ajay J. Kirtane

April 08, 2017

News Daily News

Scaffold Thrombosis Concerns With Absorb BVS Echoed in AIDA Trial

Michael O'Riordan

March 29, 2017

News Conference News ACC 2017

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

Michael O'Riordan

March 18, 2017

News Conference News ACC 2017

FDA Warns of Risk of Major Adverse Cardiac Events With Absorb BVS

Michael O'Riordan

March 18, 2017

News Conference News ACC 2017

iFR Matches FFR for Clinical Outcomes in Patients With Intermediate Lesions

Caitlin E. Cox

March 18, 2017

News Conference News ACC 2017

Replacing Aspirin With Low-Dose Rivaroxaban for Post-ACS Therapy Appears Safe

Todd Neale

March 18, 2017

News Daily News

Faster Primary PCIs Linked to Higher Stent Thrombosis Risk With Bivalirudin

Todd Neale

March 07, 2017

News Daily News

Length Matters: More Adverse Events With Absorb BVS at 1 Year in Long Lesions

L.A. McKeown

March 02, 2017

News Conference News CRT 2017

Absorb BVS: Better Technique, Better Outcomes? More Data—and More Debate

Michael O'Riordan

February 21, 2017

News Daily News

DESolve Bioresorbable Stent Compares Well With Absorb, but Longer Follow-up Needed

Michael O'Riordan

February 16, 2017

Presentation JIM 2017

The EluNIR clinical program: BIONICS and NIREUS - One Year Follow Up

Presenter: Giuseppe Musumeci

February 09, 2017

News Daily News

10-Year Follow-up of Early DES Shows Steady Risk of Late Events

L.A. McKeown

February 08, 2017

News Daily News

Cobra Stent With Ultrathin Polymer Safe, Effective but Needs Testing in Tougher Patients

Michael O'Riordan

February 03, 2017

News Daily News

Device, Operator, or Lesion: What Affects Long-term Outcomes With Bioresorbable Scaffolds?

Michael O'Riordan

February 02, 2017

News Daily News

TWENTE: Resolute and Xience Stents Show Comparable Outcomes up to 5 Years

Michael O'Riordan

January 20, 2017

News Daily News

Absorb BVS Meets Performance Goal in Diabetic Patients, but Is It Enough to Justify a Broader Label?

Yael L. Maxwell

December 23, 2016

Advertisement

Long-term MI Risk Among Stable CAD Patients: Some Clues From CORONOR

Absorb Comparable to Xience in Economic Analysis, but BVS Safety Concerns Could Alter Balance

Treating In-Stent CTOs May Be Riskier Than De Novo CTOs Despite Similar Procedural Success

The Left Main Debate: What Does it Mean for the Future of Intervention?

Stent Thrombosis and Restenosis

Scaffold Thrombosis Concerns With Absorb BVS Echoed in AIDA Trial

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

FDA Warns of Risk of Major Adverse Cardiac Events With Absorb BVS

iFR Matches FFR for Clinical Outcomes in Patients With Intermediate Lesions

Replacing Aspirin With Low-Dose Rivaroxaban for Post-ACS Therapy Appears Safe

Faster Primary PCIs Linked to Higher Stent Thrombosis Risk With Bivalirudin

Length Matters: More Adverse Events With Absorb BVS at 1 Year in Long Lesions

Absorb BVS: Better Technique, Better Outcomes? More Data—and More Debate

DESolve Bioresorbable Stent Compares Well With Absorb, but Longer Follow-up Needed

The EluNIR clinical program: BIONICS and NIREUS - One Year Follow Up

10-Year Follow-up of Early DES Shows Steady Risk of Late Events

Cobra Stent With Ultrathin Polymer Safe, Effective but Needs Testing in Tougher Patients

Device, Operator, or Lesion: What Affects Long-term Outcomes With Bioresorbable Scaffolds?

TWENTE: Resolute and Xience Stents Show Comparable Outcomes up to 5 Years

Absorb BVS Meets Performance Goal in Diabetic Patients, but Is It Enough to Justify a Broader Label?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content